AR042315A1 - Mutantes de escape del virus de la enfermedad de newcastle como vacunas marcadoras - Google Patents

Mutantes de escape del virus de la enfermedad de newcastle como vacunas marcadoras

Info

Publication number
AR042315A1
AR042315A1 ARP030104494A ARP030104494A AR042315A1 AR 042315 A1 AR042315 A1 AR 042315A1 AR P030104494 A ARP030104494 A AR P030104494A AR P030104494 A ARP030104494 A AR P030104494A AR 042315 A1 AR042315 A1 AR 042315A1
Authority
AR
Argentina
Prior art keywords
newcastle disease
monoclonal antibody
mutant
disease virus
immunogen
Prior art date
Application number
ARP030104494A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR042315A1 publication Critical patent/AR042315A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
    • G01N2333/125—Newcastle disease virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Una vacuna contra la enfermedad de Newcastle, contiene uno o más inmunógenos mutantes de la cepa NDW. El inmunógeno mutante carece del sitio de enlace antigénico en la glucoproteína F reconocido por el anticuerpo monoclonal mAb 64. Los equipos de reactivos y métodos de ensayo y ayudan a distinguir los miembros vacunados de una bandada de aves de corral, de aquéllos que pueden haber sido infectados con el virus de la enfermedad de Newcastle natural. Reivindicación 1: Una vacuna contra el virus de la enfermedad de Newcastle, que comprende aproximadamente 100-109 EID50 de un inmunógeno mutante de la cepa NDW del virus de la enfermedad de Newcastle, en donde dicho inmunógeno mutante carece del sitio de enlace antigénico en la glucoproteína F reconocido por el anticuerpo monoclonal designado mAb 54. Reivindicación 2: La vacuna tal como se reivindica en la reivindicación 1, en donde dicho inmunógeno mutante es sometido a pases sucesivos. Reivindicación 10: Un método para generar un inmunógeno mutante del virus de la enfermedad de Newcastle útil en una vacuna contra la enfermedad de Newcastle, que comprende cultivar el virus de la enfermedad de Newcastle ante la presencia del anticuerpo monoclonal designado mAb 54, de manera que dicho inmunógeno mutante se desarrolle y crezca ante la presencia de dicho anticuerpo monoclonal, y no sea neutralizado por dicho anticuerpo monoclonal.
ARP030104494A 2002-12-06 2003-12-05 Mutantes de escape del virus de la enfermedad de newcastle como vacunas marcadoras AR042315A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43151902P 2002-12-06 2002-12-06
US47141903P 2003-05-15 2003-05-15

Publications (1)

Publication Number Publication Date
AR042315A1 true AR042315A1 (es) 2005-06-15

Family

ID=32511574

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104494A AR042315A1 (es) 2002-12-06 2003-12-05 Mutantes de escape del virus de la enfermedad de newcastle como vacunas marcadoras

Country Status (10)

Country Link
US (2) US6833133B2 (es)
EP (1) EP1578374B1 (es)
JP (1) JP4785531B2 (es)
AR (1) AR042315A1 (es)
AT (1) ATE467424T1 (es)
AU (1) AU2003298838A1 (es)
CA (1) CA2508139C (es)
DE (1) DE60332555D1 (es)
TW (1) TW200502402A (es)
WO (1) WO2004052278A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100247574A1 (en) * 2007-02-21 2010-09-30 Kutub Mahmood CHIMERIC NEWCASTLE DISEASE VIRUS VLPs
WO2009102459A2 (en) * 2008-02-13 2009-08-20 Wyeth A genetic assay to identify newcastle disease virus escape mutants

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7492087A (en) * 1986-06-30 1988-01-07 Smith Kline - Rit Newcastle disease virus protein
EP0351908B1 (en) * 1988-07-18 1994-10-05 Duphar International Research B.V Live newcastle disease virus vacccines
US5250298A (en) * 1988-10-07 1993-10-05 University Of Delaware Live attenuated newcastle disease virus vaccines and preparation thereof
JP2781605B2 (ja) * 1989-06-22 1998-07-30 日本ゼオン株式会社 組み換えアビポックスウイルス
CA2181862C (en) * 1995-08-01 2009-12-22 Carla Christina Schrier Mild newcastle disease virus vaccine
DE69632235T2 (de) * 1995-10-18 2004-08-26 Akzo Nobel N.V. Newcastle-Krankheitsvirus-Kombinationsimpfstoff
EP0848956A1 (en) * 1996-12-17 1998-06-24 Dimminaco Ag/Sa/Ltd. In ovo vaccination against Newcastle Disease
WO1999002695A2 (en) * 1997-07-08 1999-01-21 Stichting Instituut Voor Dierhouderij En Diergezondheid Epitopes and active sites of paramyxoviridae proteins and uses thereof
EP0974660A1 (en) * 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
DK1383795T3 (da) 2000-11-02 2007-05-29 Intervet Int Bv Rekombinant nucleoproteinmutant fra Newcastle disease-virus som markörvaccine

Also Published As

Publication number Publication date
AU2003298838A1 (en) 2004-06-30
CA2508139C (en) 2009-09-22
WO2004052278A2 (en) 2004-06-24
CA2508139A1 (en) 2004-06-24
US6833133B2 (en) 2004-12-21
TW200502402A (en) 2005-01-16
US20040131640A1 (en) 2004-07-08
EP1578374A4 (en) 2006-12-13
WO2004052278A3 (en) 2004-09-16
AU2003298838A8 (en) 2004-06-30
EP1578374B1 (en) 2010-05-12
EP1578374A2 (en) 2005-09-28
US20050069561A1 (en) 2005-03-31
JP2006511619A (ja) 2006-04-06
JP4785531B2 (ja) 2011-10-05
US7041299B2 (en) 2006-05-09
ATE467424T1 (de) 2010-05-15
DE60332555D1 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
Fekadu et al. Efficacy of rabies vaccines against Duvenhage virus isolated from European house bats (Eptesicus serotinus), classic rabies and rabies-related viruses
ATE287947T1 (de) Orale immunisierung durch verwendung von transgenen pflanzen
DK2181715T3 (da) Kunstige T-hjælpecelle-epitoper som immunstimulatorer for syntetiske peptidimmunogener
BR9306984A (pt) Análogo de antígeno de peptídeo de um antígeno de peptídeo nativo vacina anticorpo processo para vacinar um hospedeiro necessitando deste tratamento estojo diagnóstico processos para preparar um análogo de um antiígeno de um antígeno de peptídeo nativo para preparar uma vacina para analisar uma amostra para um antígeno de peptídeo nativo e para analisar uma amostra para um anticorpo
AR053286A2 (es) Cultivo de celulas de una cepa derivada de una cepa progenitra de una especie de neospora, vacuna que las contiene, metodos para preparar dicho cultivo, metodo para preparar una vacuna con dicho cultivo, metodo para vacunar un mamifero con dicha vacuna y vacuna que comprende dichas celulas
DK0755259T3 (da) Kimære-cDNA-kloner af virussen for den infektiöse GUMBORO-syge, ekspressionsprodukter heraf og vacciner baseret derpå
DE69333814D1 (de) Genetischer impfstoff gegen den immunschwäche virus
SE8005824L (sv) Vaccin av hudparvovirus samt forfarande for dess framstellning
NO20053328L (no) Immunisering av fisk med uttrykte proteiner i planteceller.
Niqueux et al. Prime-boost vaccination with recombinant H5-fowlpox and Newcastle disease virus vectors affords lasting protection in SPF Muscovy ducks against highly pathogenic H5N1 influenza virus
AR042315A1 (es) Mutantes de escape del virus de la enfermedad de newcastle como vacunas marcadoras
ATE149569T1 (de) Verfahren zur herstellung von impfstoffen oder toxoiden
PE20060860A1 (es) Vacuna basada en epitopes neutralizantes
DE69031426T2 (de) Impfstoff zur immunisierung von katzen gegen toxoplasmen ohne verbreitung der oozysten
AR048429A1 (es) Aislados antigenicos y vacunas del virus de la bursitis infecciosa
Amezian et al. Complete moult of an undescribed resident taxon of the Reed Warbler Acrocephalus scirpaceus/baeticatus complex in the Smir marshes, Northern Morocco
HUP0104125A2 (hu) Eljárás szárnyasok intradermális immunizálására inaktivált vakcinákkal
Jacobson et al. Antibody responses of western diamondback rattlesnakes (Crotalus atrox) to inactivated ophidian paramyxovirus vaccines
AR038485A1 (es) Seleccion de cepas de eimeria de aves de corral a traves de esporozoitos extra-intestinales
Mehrabadi et al. Comparison of autogenous and commercial H9N2 avian influenza vaccines in a challenge with recent dominant virus
Ginter The dentition of a eugeneodontiform shark from the Lower Pennsylvanian of Derbyshire, UK
Kumar Where do we come from? What are we? Where are we going?
Dickerson et al. Vaccination against Ich
Yadin Spray vaccination of turkeys against Newcastle disease
Bihun et al. Coronavirus infections in the laboratory rat: degree of cross protection following immunization with a heterologous strain.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal